新冠肺炎患者的血栓预防

IF 0.4 Q4 PERIPHERAL VASCULAR DISEASE

Acta Angiologica Pub Date : 2022-01-28 DOI:10.5603/aa.2021.0016

M. Dybowska, D. Dybowski, M. Szturmowicz, K. Lewandowska, M. Sobiecka, D. Wyrostkiewicz, W. Tomkowski

{"title":"新冠肺炎患者的血栓预防","authors":"M. Dybowska, D. Dybowski, M. Szturmowicz, K. Lewandowska, M. Sobiecka, D. Wyrostkiewicz, W. Tomkowski","doi":"10.5603/aa.2021.0016","DOIUrl":null,"url":null,"abstract":"For two years, the entire world has been grappling with the new challenge that is the COVID-19 pandemic. In December 2019 in China's largest province, Wuhan, Severe Acute Respiratory Syndrome- Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to COVID-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomized trials.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"33","resultStr":"{\"title\":\"Thromboprophylaxis in patients with Covid-19\",\"authors\":\"M. Dybowska, D. Dybowski, M. Szturmowicz, K. Lewandowska, M. Sobiecka, D. Wyrostkiewicz, W. Tomkowski\",\"doi\":\"10.5603/aa.2021.0016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For two years, the entire world has been grappling with the new challenge that is the COVID-19 pandemic. In December 2019 in China's largest province, Wuhan, Severe Acute Respiratory Syndrome- Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to COVID-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomized trials.\",\"PeriodicalId\":41754,\"journal\":{\"name\":\"Acta Angiologica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"33\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Angiologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/aa.2021.0016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Angiologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/aa.2021.0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 33

摘要

两年来，全世界都在努力应对COVID-19大流行这一新的挑战。2019年12月，在中国最大的省份武汉，一名严重呼吸衰竭患者被发现患有严重急性呼吸综合征-冠状病毒2 (SARS-CoV-2)。不久之后，在世界所有区域都发现了感染。到目前为止，全球已确诊2.65亿例感染，其中520万感染者因COVID-19而死亡。感染SARS-CoV-2与心血管并发症，特别是血栓栓塞性并发症的风险增加有关。低分子量肝素是预防COVID-19患者血栓栓塞性并发症的一种基本形式。关于低分子肝素根据疾病严重程度的最佳剂量仍存在争议，这一问题需要进一步的随机试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Thromboprophylaxis in patients with Covid-19

For two years, the entire world has been grappling with the new challenge that is the COVID-19 pandemic. In December 2019 in China's largest province, Wuhan, Severe Acute Respiratory Syndrome- Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to COVID-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomized trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta Angiologica PERIPHERAL VASCULAR DISEASE-

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

26 weeks

期刊介绍： Acta Angiologica is a bilingual (Polish/English) quarterly for angiologists and vascular surgeons as well as for other doctors interested in vascular disorders. Original papers, reviews, case reports and letters submitted by authors from different countries, concerning physiology, pathology, presentation, diagnostics and treatment of vascular system, are published. Thorough contents of Acta Angiologica provide valuable information about modern diagnostic and therapeutic issues as well as advances in basic sciences and pharmacology.